AMA submission to the consultation on intravitreal eye injections

The AMA supports clinician-led, evidence-based reforms that do not compromise patient safety or access. We have consistently warned any change must not increase patient costs or reduce access, especially for vulnerable groups. We strongly endorse the Government’s decision to maintain current MBS fee levels for IVI, as any reduction would risk service viability and patient access, particularly in rural and remote areas. To protect affordability and equity, the AMA calls for transparent certification processes, monitoring of out-of-pocket costs, and investment in bulk-billing and public outpatient services. The AMA opposes any expansion of IVI provision to non-medical practitioners without rigorous clinical governance, regulatory oversight, and evidence of safety and efficacy.